BOCA RATON, FL / ACCESS Newswire / October 16, 2025 / Entero Therapeutics, Inc. (NASDAQ:ENTO) ("ENTO" or the "Company") a company pioneering innovation at the intersection of biotechnology and AI-driven energy infrastructure launches Grid AI Corp., to redefine how artificial intelligence infrastructure connects to the power grid. According to the company, the rise of artificial intelligence is driving the fastest... Read More

BOCA RATON, FL, NY / ACCESS Newswire / October 14, 2025 / Entero Therapeutics (NASDAQ:ENTO) has reinvented itself in a way few public companies dare. By acquiring GRID AI , it has stepped directly into one of the most urgent races of the decade: making sure energy can keep pace with the accelerating appetite of artificial intelligence. The Entero story is now less about enzymes and long clinical trials. It is now about... Read More

Transaction positions ENTO in the high-growth AI energy-infrastructure market, amid a surge of multi-billion-dollar hyperscaler spending on data centers, and rapid growth in behind-the-meter energy storage solutions BOCA RATON, FL / ACCESS Newswire / October 1, 2025 / Entero Therapeutics, Inc. (NASDAQ:ENTO) ("ENTO" or the "Company") today announced it has acquired 100% of GRID AI Corp ("GRID AI"), a grid-edge, AI-driven... Read More

Transaction positions ENTO in the high-growth AI energy-infrastructure market, amid a surge of multi-billion-dollar hyperscaler spending on data centers, and rapid growth in behind-the-meter energy storage solutions Boca Raton, Florida--(Newsfile Corp. - October 1, 2025) - Entero Therapeutics, Inc. (NASDAQ: ENTO) ("ENTO" or the "Company") today announced it has acquired 100% of GRID AI Corp ("GRID AI"), a grid-edge,... Read More

Boca Raton, Florida--(Newsfile Corp. - August 14, 2025) - Entero Therapeutics, Inc. (NASDAQ: ENTO) (the "Company"), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, announced that, it will effect a 1 for 3 reverse stock split of its common stock. The Company expects its common stock to begin trading on a split-adjusted basis on... Read More

Boca Raton, Florida--(Newsfile Corp. - August 11, 2025) - Entero Therapeutics, Inc. (NASDAQ: ENTO) (the "Company"), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, today announced that it has entered into definitive agreements with institutional investors for the purchase and sale of approximately $3 million of pre-funded and... Read More

Boca Raton, Florida--(Newsfile Corp. - March 24, 2025) - Entero Therapeutics, Inc. (NASDAQ: ENTO) ("Entero" or the "Company"), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, announced today that Entero has successfully negotiated and signed a rescission agreement (the "Rescission Agreement") with 100% of the previous... Read More

BOCA RATON, Fla., Feb. 14, 2025 (GLOBE NEWSWIRE) -- Entero Therapeutics, Inc. (Nasdaq: ENTO) (“Entero” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, announced today that the board of directors has appointed Mr. Richard Paolone as the interim CEO of the Company. Richard Paolone is a Toronto-based securities... Read More

BOCA RATON, Fla., Feb. 07, 2025 (GLOBE NEWSWIRE) -- Entero Therapeutics, Inc. (Nasdaq: ENTO) (“Entero” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, announced today that it has secured a $2 million revolving loan agreement and subsequently appointed three new members to its Board of Directors. As a... Read More

BOCA RATON, Fla., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Entero Therapeutics, Inc. , (NASDAQ: ENTO), (“Entero Therapeutics” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, today announced that James Sapirstein, Chairman and CEO of Entero Therapeutics, will moderate the "CEO Insights: Lessons Learned & Strategies... Read More

Proposed merger to create Nasdaq-listed, clinical-stage biopharmaceutical company focused on advancing (i) Journey’s next-gen, first-in-class ADC-rivalling, nano-immunoconjugates (“NIC”) platform and therapeutic products for unmet medical needs in oncology and autoimmune diseases and (ii) Entero’s gastrointestinal product pipeline for treating unmet metabolic and rare genetic diseases; The NIC platform technology is invented... Read More

BOCA RATON, Fla., Sept. 10, 2024 (GLOBE NEWSWIRE) -- Entero Therapeutics, Inc. , (NASDAQ: ENTO), (“Entero Therapeutics” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, today announced its entry into a binding letter of intent (the “Letter of Intent”) with Data Vault Holdings, Inc. (“Data Vault”), a privately... Read More

BOCA RATON, Fla., Aug. 23, 2024 (GLOBE NEWSWIRE) -- Entero Therapeutics, Inc., (NASDAQ: ENTO), (“Entero Therapeutics” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, today announced that it received a letter from the Listing Qualifications Department of the Nasdaq Stock Market (“Nasdaq”) advising that,... Read More

BOCA RATON, Fla., July 31, 2024 (GLOBE NEWSWIRE) -- Entero Therapeutics, Inc. , (NASDAQ: ENTO), (“Entero Therapeutics” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, today released a letter from James Sapirstein, the Company’s Chairman and CEO, to provide stockholders with a business update. LETTER FROM OUR... Read More

BOCA RATON, Fla., July 11, 2024 (GLOBE NEWSWIRE) -- Entero Therapeutics, Inc. (“Entero” or the “Company”) (NASDAQ: ENTO), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, today announced it has entered into agreements with certain holders of its existing warrants exercisable for 1,762,674 shares of its common stock, in the... Read More

BOCA RATON, Fla., July 09, 2024 (GLOBE NEWSWIRE) -- Entero Therapeutics, Inc. , (NASDAQ: ENTO), (“Entero Therapeutics” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, today announced that an abstract has been accepted for oral presentation at the 20 th International Celiac Disease Symposium (ICDS) 2024 taking... Read More

New VCIEL scale provides a more sensitive and quantitative metric of small intestinal health for monitoring Celiac Disease severity and treatment efficacy Special editorial highlights the potential importance of VCIEL for CeD research and clinical trials BOCA RATON, Fla., June 27, 2024 (GLOBE NEWSWIRE) -- Entero Therapeutics, Inc. , (NASDAQ: ENTO), (“Entero Therapeutics” or the “Company”), a clinical-stage biopharmaceutical... Read More

BOCA RATON, Fla., May 22, 2024 (GLOBE NEWSWIRE) -- Entero Therapeutics, Inc. (formerly First Wave BioPharma, Inc.) (Nasdaq: ENTO) (“Entero” or the “Company”), a late clinical-stage biopharmaceutical company focused on the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, today announced that it will present at the 2024 BIO International Convention which will be held June 3-6, 2024, in San... Read More

BOCA RATON, Fla., May 20, 2024 (GLOBE NEWSWIRE) -- Entero Therapeutics, Inc. , (NASDAQ: ENTO), (“Entero Therapeutics” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, yesterday presented two posters on celiac disease research at the 2024 Digestive Disease Week (DDW 2024) Conference in Washington, D.C. The... Read More

Rebranding introduced as Company advances toward Phase 3 clinical trial with lead asset – latiglutenase for the treatment of celiac disease New Nasdaq ticker symbol is “ENTO” effective May 17, 2024 BOCA RATON, Fla., May 16, 2024 (GLOBE NEWSWIRE) -- Entero Therapeutics, Inc. (formerly First Wave BioPharma, Inc.) (Nasdaq: ENTO) (“Entero” or the “Company”), a late clinical-stage biopharmaceutical company focused on the... Read More

BOCA RATON, Fla., May 10, 2024 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc. , (NASDAQ: FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, announced today that it has entered into a definitive securities purchase agreement with a certain institutional investor for the purchase and... Read More

BOCA RATON, Fla., May 09, 2024 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc. , (NASDAQ: FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, today announced that in honor of Celiac Disease Awareness Month in May, it will partner with Celiac Journey, a celiac disease patient advocacy... Read More

BOCA RATON, Fla., April 24, 2024 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc. , (NASDAQ: FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, today announced research generated from two previously completed Phase 2 clinical trials of latiglutenase has been published in the special... Read More

BOCA RATON, Fla., April 17, 2024 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc. , (NASDAQ: FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, today announced that James Sapirstein, Chairman and CEO of First Wave BioPharma, will present at the Planet MicroCap Showcase, which will be... Read More

BOCA RATON, Fla., April 15, 2024 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc. , (NASDAQ: FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, today announced that James Sapirstein, Chairman and CEO of First Wave BioPharma, will participate in the Longwood Healthcare Leaders... Read More

Poster presentations to highlight new quantitative and serologic diagnostic methods for Celiac Disease detection and determination of intestinal mucosal health New tools may serve as companion diagnostics for identifying seroactive patients and for monitoring the efficacy of Latiglutenase, the Company’s Celiac Disease therapeutic program BOCA RATON, Fla., March 18, 2024 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc. ,... Read More

Latiglutenase is a potentially first-in-class oral biotherapeutic for the treatment of celiac disease James Sapirstein, Chairman and Chief Executive Officer, to continue leading First Wave BioPharma; Jack Syage, Ph.D., named President and Chief Operating Officer A strategic U.S. commercial license agreement with a global pharmaceutical company and concurrent institutional investment expected to close in 2H’24 Conference Call... Read More

BOCA RATON, Fla., March 05, 2024 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc. , (NASDAQ: FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, today announced James Sapirstein, Chairman, President and CEO, will participate in a “fireside chat” with Jonathan Aschoff, Ph.D., Managing... Read More

BOCA RATON, Fla., March 04, 2024 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc. , (NASDAQ: FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, announced today that it has entered into a definitive securities purchase agreement with a certain institutional investor for the purchase... Read More

BOCA RATON, Fla., Feb. 13, 2024 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc. , (NASDAQ: FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, today announced that James Sapirstein, Chairman and CEO of First Wave BioPharma, will present at the BIO CEO & Investor Conference, which is... Read More

BOCA RATON, Fla., Jan. 23, 2024 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc. , (NASDAQ: FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, today announced that it will present at the DealFlow MicroCap Conference, which will be held January 30 – February 1, 2024 at the Caesars... Read More

BOCA RATON, Fla., Jan. 17, 2024 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc. , (NASDAQ: FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, today announced that James Sapirstein, Chairman and CEO of First Wave BioPharma, will present at the Sequire Investor Summit 2024, which is... Read More

BOCA RATON, Fla., Jan. 04, 2024 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc. , (NASDAQ: FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, today announced that James Sapirstein, Chairman and CEO of First Wave BioPharma, has issued a Letter to Stockholders highlighting the... Read More

BOCA RATON, Fla., Dec. 27, 2023 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc. (“First Wave BioPharma” or the “Company”) (NASDAQ: FWBI), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, today announced it has entered into agreements with certain holders of its existing warrants exercisable for 881,337 shares of its common stock,... Read More

BOCA RATON, Fla., Dec. 27, 2023 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc. , (NASDAQ: FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, today announced that it has entered a non-binding term sheet to sell its Niclosamide program for the treatment of inflammatory bowel diseases... Read More

Phase 3-ready latiglutenase, a targeted oral biotherapeutic for celiac disease, will expand First Wave BioPharma’s late-stage gastrointestinal (GI) disease clinical pipeline A concurrent institutional investment and a strategic U.S. license agreement with a global pharmaceutical company is anticipated to be completed post-closing BOCA RATON, Fla., Dec. 18, 2023 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc. , (NASDAQ: FWBI),... Read More

BOCA RATON, Fla., Dec. 14, 2023 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc. (NASDAQ: FWBI) (“First Wave BioPharma,” “First Wave” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, today announced that the Company’s stockholders have approved all proposals voted on at the Company’s special meeting of... Read More

BOCA RATON, Fla., Dec. 06, 2023 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc. (NASDAQ: FWBI) (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, announced today the company will participate in BIO Partnering @JPM being held January 8-12, 2024 in San Francisco. Details of the events are as... Read More

BOCA RATON, Fla., Dec. 05, 2023 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc. , (NASDAQ: FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, today announced that James Sapirstein, Chairman, President, and CEO of First Wave BioPharma, will moderate a panel discussion on cross-border... Read More

BOCA RATON, Fla., Oct. 10, 2023 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc. , (NASDAQ: FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, today announced that Chairman, President, and CEO of First Wave BioPharma James Sapirstein’s presentation at the 2023 BIO Investor Forum will... Read More

BOCA RATON, Fla., Oct. 03, 2023 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc. , (NASDAQ: FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, today announced that James Sapirstein, Chairman, President, and CEO of First Wave BioPharma, will give a presentation at the 2023 Roth... Read More

BOCA RATON, Fla., Sept. 15, 2023 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ:FWBI), (“First Wave” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, today announced that James Sapirstein, President and CEO, will make a company presentation at the BIO Investor Forum being held October 17-18, 2023, at... Read More

BOCA RATON, Fla., Sept. 14, 2023 (GLOBE NEWSWIRE) - - First Wave BioPharma, Inc. (“First Wave BioPharma” or the “Company”) (NASDAQ: FWBI), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, today announced it has entered into agreements with certain holders of its existing warrants exercisable for 5,882,036 shares of its common... Read More

BOCA RATON, Fla., Sept. 14, 2023 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc. , (NASDAQ:FWBI), (“First Wave” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, today announced an agreement with Sanofi (NASDAQ: SNY) to license Capeserod, a selective 5-HT4 receptor partial agonist, which First Wave will... Read More

BOCA RATON, Fla., Sept. 05, 2023 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc. , (NASDAQ:FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, today announced that James Sapirstein, Chairman and Chief Executive Officer, will deliver a virtual presentation at the H.C. Wainwright 25 th... Read More

BOCA RATON, Fla., July 19, 2023 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc. (NASDAQ:FWBI) (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal diseases, today announced the pricing of a public offering of 3,285,000 shares of its common stock (or pre-funded warrants in lieu thereof) and warrants to... Read More

BOCA RATON, Fla., July 13, 2023 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc. , (NASDAQ:FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, today announced the Company has received topline results from the Company’s Phase 2 SPAN clinical trial investigating an enhanced enteric... Read More

BOCA RATON, Fla., July 05, 2023 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc. , (NASDAQ:FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, today announced that James Sapirstein, Chairman, President and CEO of First Wave BioPharma, has issued a Letter to Stockholders providing an... Read More

BOCA RATON, Fla., June 28, 2023 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc. (NASDAQ:FWBI) (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, today announced that the final patient was dosed in the Phase 2 SPAN clinical trial investigating an enhanced enteric microgranule delivery... Read More

BOCA RATON, Fla., June 27, 2023 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc. (NASDAQ:FWBI) (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, today announced the publication of two patent applications for composition of matter and methods of use claims governing the Company’s enhanced... Read More

BOCA RATON, Fla., June 15, 2023 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc. (NASDAQ:FWBI) (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, announced that it will attend the Cystic Fibrosis Research Institute’s (CFRI) 36 th National Cystic Fibrosis Education Conference being held July... Read More

BOCA RATON, Fla., June 13, 2023 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc. ("First Wave BioPharma" or the “Company”) (NASDAQ: FWBI), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, today announced it has entered into agreements with certain holders of its existing warrants exercisable for 1,681,667 shares of its common... Read More

Two-thirds of patients have completed study, final patients being dosed Top line data read-out on track for July 2023 BOCA RATON, Fla., June 13, 2023 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc. ("First Wave BioPharma" or the “Company”) (NASDAQ: FWBI), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, today announced that it... Read More

BOCA RATON, Fla., May 15, 2023 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc. (NASDAQ: FWBI) (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, announced today that James Sapirstein, Chief Executive Officer of First Wave BioPharma, will present at the 2023 BIO International Conference on... Read More

Top line data read-out on track for July 2023 BOCA RATON, Fla., May 11, 2023 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc. ("First Wave BioPharma" or the “Company”) (NASDAQ: FWBI), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, today announced that it has completed patient screening in its ongoing Phase 2 SPAN clinical trial... Read More

BOCA RATON, Fla., May 02, 2023 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc. (NASDAQ: FWBI) (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, announced today the company will participate in the EF Hutton Inaugural Global Conference being held May 10-11, 2023 at the Plaza Hotel in New... Read More

Three U.S. clinical trial sites actively screening and enrolling patients Top line data of adrulipase in Cystic Fibrosis patients expected in July 2023 BOCA RATON, Fla., April 25, 2023 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc. ("First Wave BioPharma" or the “Company”) (NASDAQ: FWBI), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI)... Read More

BOCA RATON, Fla., March 13, 2023 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc. ("First Wave BioPharma" or the “Company”) (NASDAQ: FWBI), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, today announced that it has entered into a definitive agreement with a certain institutional investor for the issuance and sale of 1,023,018... Read More

BOCA RATON, Fla., March 10, 2023 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc. (NASDAQ:FWBI) (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, announced that the second patient was dosed in the Phase 2 SPAN clinical trial investigating an enhanced enteric microgranule delivery... Read More

BOCA RATON, Fla., March 09, 2023 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc. (NASDAQ:FWBI) (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, announced that the first patient was dosed in the Phase 2 SPAN clinical trial investigating an enhanced enteric microgranule delivery... Read More

BOCA RATON, Fla., Feb. 28, 2023 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc. (NASDAQ:FWBI) (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, announced James Sapirstein, Chairman, President and CEO, will participate in a “fireside chat” with Jonathan Aschoff, Ph.D., Managing Director... Read More

BOCA RATON, Fla., Feb. 21, 2023 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc. (NASDAQ:FWBI) (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, today announced that an abstract entitled, “Results from an Open-Label, Phase 2 Study with Escalating Doses of Adrulipase Alfa on top of a Stable... Read More

BOCA RATON, Fla., Feb. 13, 2023 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc. , (NASDAQ:FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, today announced that James Sapirstein, Chairman, President and CEO of First Wave BioPharma, has issued a Letter to Stockholders providing an... Read More

BOCA RATON, Fla., Feb. 07, 2023 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc. (NASDAQ:FWBI) (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, today announced that on February 6, 2023, the Company received formal notice from the Nasdaq Hearing Panel (the “Panel”) indicating that First... Read More

BOCA RATON, Fla., Feb. 02, 2023 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc. (NASDAQ:FWBI) (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, today announced that the first patient was screened for the Phase 2 SPAN clinical trial investigating an enhanced enteric microgranule delivery... Read More

BOCA RATON, Fla., Jan. 31, 2023 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc. (NASDAQ:FWBI) (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, today announced that the Company will initiate its planned Phase 2 clinical trial of an enhanced enteric microgranule delivery formulation for... Read More

BOCA RATON, Fla., Jan. 30, 2023 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc. (NASDAQ:FWBI) (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, announced James Sapirstein, Chairman, President and CEO, will present at the BIO CEO & Investor Conference being held February 6-9, 2023, at the... Read More

BOCA RATON, Fla., Jan. 25, 2023 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc. (NASDAQ: FWBI) (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, announced today the company has filed a U.S. Provisional Patent application involving composition of matter improvements designed to enhance... Read More

BOCA RATON, Fla., Jan. 24, 2023 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc. (NASDAQ:FWBI) (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, announced James Sapirstein, Chairman, President and CEO, will present at the Sequire Biotechnology Conference being held virtually on February 2,... Read More

BOCA RATON, Fla., Jan. 13, 2023 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc. (NASDAQ:FWBI) (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, announced that the U.S. Food and Drug Administration (FDA) is reviewing the Investigational New Drug (IND) amendment for the planned Phase 2... Read More

BOCA RATON, Fla., Jan. 13, 2023 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc. (NASDAQ:FWBI) (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, today announced that the Company’s stockholders have approved all proposals voted on at the Company’s special meeting of stockholders (the... Read More

BOCA RATON, Fla., Jan. 09, 2023 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc. , (NASDAQ:FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, today announced that it has adjourned its Special Meeting of Stockholders (the “Special Meeting”) in order to provide stockholders additional... Read More

Upon IND clearance, Phase 2 clinical trial investigating adrulipase as a treatment for exocrine pancreatic insufficiency associated with cystic fibrosis and chronic pancreatitis is expected to initiate in early 2023 with topline clinical data anticipated in the first half of 2023 BOCA RATON, Fla., Nov. 30, 2022 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc. (NASDAQ:FWBI) (“First Wave BioPharma” or the “Company”), a... Read More